| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
30,755 |
28,743 |
$6.44M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
28,495 |
26,943 |
$6.19M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
13,105 |
12,218 |
$2.59M |
| 41899 |
Unlisted procedure, dentoalveolar structures |
908 |
875 |
$1.28M |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
4,232 |
3,926 |
$654K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,222 |
1,143 |
$486K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
11,364 |
10,418 |
$388K |
| 80053 |
Comprehensive metabolic panel |
26,999 |
24,545 |
$230K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
13,253 |
12,310 |
$222K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
10,029 |
8,376 |
$212K |
| 71046 |
Radiologic examination, chest; 2 views |
6,565 |
6,239 |
$208K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
22,544 |
20,288 |
$167K |
| 71045 |
Radiologic examination, chest; single view |
5,640 |
5,252 |
$142K |
| 70450 |
Computed tomography, head or brain; without contrast material |
960 |
892 |
$138K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
743 |
705 |
$130K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,259 |
1,102 |
$110K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,371 |
1,234 |
$108K |
| 81025 |
|
9,247 |
8,606 |
$68K |
| J3490 |
Unclassified drugs |
30,043 |
18,139 |
$62K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
134 |
127 |
$59K |
| 85027 |
|
8,768 |
8,229 |
$53K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
997 |
951 |
$52K |
| 83690 |
|
7,218 |
6,710 |
$49K |
| 62323 |
|
411 |
365 |
$45K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
179 |
170 |
$44K |
| 84484 |
|
5,252 |
4,804 |
$43K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
7,664 |
6,967 |
$41K |
| 81001 |
|
10,272 |
9,601 |
$34K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
6,723 |
6,239 |
$27K |
| 59025 |
Fetal non-stress test |
320 |
264 |
$25K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
936 |
766 |
$24K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,609 |
2,423 |
$22K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,516 |
1,367 |
$21K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
326 |
246 |
$21K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
846 |
741 |
$20K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
74 |
72 |
$20K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
331 |
325 |
$15K |
| 0002A |
|
273 |
272 |
$14K |
| 0001A |
|
271 |
265 |
$14K |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
10,373 |
5,828 |
$13K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
896 |
807 |
$12K |
| 81003 |
|
4,735 |
4,478 |
$11K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
405 |
354 |
$10K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,944 |
2,656 |
$10K |
| 82728 |
|
914 |
889 |
$10K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
39 |
38 |
$10K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
208 |
109 |
$10K |
| 80050 |
General health panel |
138 |
138 |
$8K |
| 80061 |
Lipid panel |
347 |
331 |
$8K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,957 |
1,798 |
$8K |
| J2704 |
Injection, propofol, 10 mg |
2,898 |
2,723 |
$6K |
| 82803 |
|
432 |
410 |
$6K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
2,526 |
2,330 |
$5K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
593 |
554 |
$5K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
754 |
714 |
$5K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
12 |
12 |
$5K |
| 64493 |
|
14 |
12 |
$5K |
| 87430 |
|
283 |
254 |
$4K |
| 84443 |
Thyroid stimulating hormone (TSH) |
167 |
150 |
$4K |
| 83605 |
|
471 |
453 |
$4K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,992 |
1,851 |
$3K |
| 87070 |
|
267 |
241 |
$3K |
| 84466 |
|
393 |
383 |
$3K |
| 83735 |
|
425 |
389 |
$3K |
| 87581 |
|
74 |
72 |
$3K |
| 87486 |
|
74 |
72 |
$3K |
| G0378 |
Hospital observation service, per hour |
38 |
27 |
$3K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
189 |
182 |
$3K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
1,801 |
1,576 |
$3K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,064 |
996 |
$3K |
| 20553 |
|
132 |
113 |
$2K |
| 64483 |
|
15 |
14 |
$2K |
| 64494 |
|
14 |
12 |
$2K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
12 |
12 |
$2K |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
720 |
658 |
$2K |
| 83880 |
|
47 |
39 |
$2K |
| 83540 |
|
407 |
397 |
$2K |
| 84439 |
|
115 |
106 |
$2K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
12 |
12 |
$1K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
90 |
81 |
$1K |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
942 |
793 |
$1K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
79 |
77 |
$999.60 |
| 80320 |
|
27 |
25 |
$948.22 |
| 76942 |
|
50 |
40 |
$846.99 |
| 94060 |
|
14 |
14 |
$773.45 |
| 73630 |
|
28 |
24 |
$730.26 |
| 0011A |
|
12 |
12 |
$715.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
396 |
352 |
$706.85 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
28 |
26 |
$672.32 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
28 |
26 |
$672.32 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
553 |
528 |
$617.12 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
44 |
37 |
$608.98 |
| 94729 |
|
14 |
14 |
$602.13 |
| 0012A |
|
13 |
13 |
$585.00 |
| 73130 |
|
12 |
12 |
$553.92 |
| 94618 |
|
13 |
13 |
$535.69 |
| 85379 |
|
43 |
28 |
$466.83 |
| Q3014 |
Telehealth originating site facility fee |
20 |
18 |
$455.29 |
| 94726 |
|
14 |
14 |
$448.18 |
| 86140 |
|
58 |
43 |
$425.35 |
| 82962 |
|
166 |
157 |
$412.72 |
| 80143 |
|
12 |
12 |
$377.90 |
| 20610 |
|
15 |
12 |
$365.37 |
| 87081 |
|
52 |
51 |
$330.28 |
| 87420 |
|
14 |
14 |
$271.91 |
| 82607 |
|
27 |
26 |
$267.62 |
| J8597 |
Antiemetic drug, oral, not otherwise specified |
288 |
266 |
$210.34 |
| 73562 |
|
12 |
12 |
$200.16 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
305 |
293 |
$188.95 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
80 |
71 |
$150.56 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
104 |
62 |
$137.33 |
| 85652 |
|
31 |
29 |
$135.23 |
| Q9965 |
Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml |
48 |
48 |
$127.01 |
| 99199 |
Unlisted special service, procedure or report |
15 |
15 |
$115.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
190 |
184 |
$110.19 |
| 96376 |
|
30 |
25 |
$98.21 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
37 |
37 |
$80.75 |
| 87210 |
|
13 |
13 |
$47.50 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
24 |
24 |
$42.38 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
25 |
25 |
$41.70 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
31 |
26 |
$39.24 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
13 |
12 |
$34.17 |
| J2004 |
Injection, lidocaine hcl with epinephrine, 1 mg |
12 |
12 |
$18.50 |
| 91300 |
|
553 |
508 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
29 |
24 |
$0.00 |
| A9270 |
Non-covered item or service |
1,009 |
612 |
$0.00 |
| 91301 |
|
25 |
25 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
13 |
12 |
$0.00 |